trending Market Intelligence /marketintelligence/en/news-insights/trending/rrbf6zbmer7n2x8mhw4zwg2 content esgSubNav
In This List

EyeGate Pharmaceuticals receives Nasdaq noncompliance notice

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


EyeGate Pharmaceuticals receives Nasdaq noncompliance notice

Eyegate Pharmaceuticals Inc. received a notice from the Nasdaq Stock Market for failing to meet the $1 minimum bid price listing requirement.

To regain compliance, the closing bid price of the company's common stock must reach at least $1 per share for a minimum of 10 consecutive business days. The Waltham, Mass.-based pharmaceutical company has 180 days, or until Sept. 17, to achieve compliance.

If EyeGate fails to meet compliance by the deadline, it may be granted a second 180-day compliance period.

The company previously received a Nasdaq noncompliance notice for failing to meet the listing requirement of a minimum $2.5 million shareholders equity.

EyeGate is a clinical-stage specialty pharmaceutical company which focuses on treating diseases and disorders of the eye.